Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global ...
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ant ...
Olema Pharmaceuticals, Inc. ('Olema” or 'Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...
Sana Biotechnology said a patient with type 1 diabetes transplanted with UP421, an allogeneic primary islet cell therapy, ...
Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...
An open-label non–HLA-A*02 cohort showed a 0.7% annualized recurrence rate after primary immunization with GLSI-100, measured over an average 1.2 patient-years of exposure. Historical comparison to ...
Dyne Therapeutics' Z-basivarsen led to gains in motor function and cognition for myotonic dystrophy type 1, and is entering a ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results